A method of preparing a .sup.64Cu-BaBaSar-RGD.sub.2 solution is provided. The method includes lyophilizing a solution of BaBaSar-RGD.sub.2 and adding a .sup.64Cu solution to the lyophilized BaBaSar-RGD.sub.2.

The present disclosure is generally related to methods, systems and devices for direct production of a radioisotope-based cancer treatment pharmaceutical directly from a corresponding non-radioactive drug molecule precursor by irradiating the non-radioactive drug molecule precursor using neutrons produced by an electronic neutron generator array or other neutron generator sources.

The invention provides a method for producing a solution containing .sup.211At.sup.− (astatide ion) at a high radiochemical purity by using .sup.211At obtained by a nuclear reaction as a starting material, including a step of adding a reducing agent to a solution containing an impurity derived from .sup.211At. The invention also provides a solution containing .sup.211At.sup.− (astatide ion) at a radiochemical purity of not less than 30%.

The radiopharmaceutical .sup.177Lu-PSMA I&T is provided, including in high purities with extended shelf life. Further provided are methods of synthesis of .sup.177Lu-PSMA I&T and pharmaceutical compositions and methods of treatment that comprise .sup.177Lu-PSMA I&T.

The present disclosure relates to gastrin-releasing peptide receptor (GRPR) targeting radiopharmaceuticals and uses thereof. In particular, the present disclosure relates to a pharmaceutical composition comprising radiolabeled GRPR-antagonist and a surfactant. The present disclosure also relates to radiolabeled GRPR-antagonist for use in treating or preventing a cancer.

The radiopharmaceutical .sup.177Lu-PSMA I&T is provided, including in high purities with extended shelf life. Further provided are methods of synthesis of .sup.177Lu-PSMA I&T and pharmaceutical compositions and methods of treatment that comprise .sup.177Lu-PSMA I&T.

The present disclosure relates to methods for radiolabelling PSMA binding ligands with a radioactive isotope, preferably .sup.68Ga, .sup.67Ga or .sup.64Cu, and their kits.

A method for producing .sup.225Ac solution includes steps (I) to (III): a step (I) of passing a solution containing .sup.226Ra and .sup.225Ac through a solid-phase extraction agent (a) that contains a compound represented by formula (A) so as to cause the solid-phase extraction agent (a) to retain .sup.225Ac; a step (II) of passing a liquid containing an eluate, which is obtained by eluting the retained .sup.225Ac from the solid-phase extraction agent (a), through a solid-phase extraction agent (b) that contains a compound represented by formula (B) so as to cause the solid-phase extraction agent (b) to retain .sup.225Ac; and a step (III) of eluting the retained .sup.225Ac from the solid-phase extraction agent (b) to obtain an .sup.225Ac solution.

##STR00001##

##STR00002##

The present invention relates to cell radiolabelling agents. The invention provides a method of preparing oxine-containing cell radiolabelling agents, a kit for the preparation of oxine-containing cell radiolabelling agents and a formulation for the preparation of oxine-containing cell radiolabelling agents, in particular .sup.89Zr-oxine cell radiolabelling agents.

A radiopeptide is provided which comprises (a) a radionuclide, wherein the radionuclide is terbium-161, (b) a chelator coordinating terbium-161, and (c) a peptide or peptide analogue, which is a somatostatin receptor (SSTR) antagonist. The radiopeptide is suitable for use in the treatment of tumor diseases.